DUBLIN, Dec. 6, 2023 /PRNewswire/ -- The 'Oligometastatic Disease - Epidemiology Forecast - 2032' report has been added to  ResearchAndMarkets.com's offering.

都柏林，2023年12月6日/PRNewswire/——ResearchAndMarkets.com的产品中增加了“寡转移性疾病-流行病学预测-2032”报告。

This  report delivers an in-depth understanding of the oligometastatic disease, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

本报告深入了解了美国，EU4（德国，西班牙，意大利和法国）以及英国和日本的寡转移性疾病，历史和预测流行病学。

As the market is derived using a patient-based model, the oligometastatic disease epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total oligometastatic disease cases, oligometastatic disease cases by major cancer indications, type-specific cases of oligometastatic disease, total oligorecurrent cases, and oligorecurrent cases by major cancer indications in the 7MM covering the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2019 to 2032.The accurate diagnosis of the oligometastatic disease relies on advanced imaging techniques, such as positron emission tomography-computed tomography (PET-CT) and magnetic resonance imaging (MRI), to identify and localize metastatic lesions..

由于市场是使用基于患者的模型得出的，因此报告中的寡转移性疾病流行病学一章提供了历史和预测的流行病学，按寡转移性疾病总病例，按主要癌症适应症划分的寡转移性疾病病例，寡转移性疾病的特定类型病例，总寡复发病例，2019年至2032年，覆盖美国，欧盟4国（德国，法国，意大利，西班牙）和英国以及日本的7MM主要癌症适应症导致的寡聚复发病例。寡聚转移性疾病的准确诊断依赖于先进的成像技术，例如正电子发射断层扫描计算机断层扫描（PET-CT）和磁共振成像（MRI），识别和定位转移性病变。。

Key Highlights

主要亮点

The oligometastatic disease is characterized by limited metastatic spread, typically involving one to five distant sites beyond the primary tumor.

寡转移性疾病的特征是转移扩散有限，通常涉及原发肿瘤以外的一到五个远处。

Even among cancer researchers, the oligometastatic concept is not always well understood. The most important idea is that metastasis is a spectrum, both in the number of tumors and the speed at which the disease spreads.

即使在癌症研究人员中，寡转移的概念也并不总是很好理解。最重要的想法是转移是一个频谱，无论是肿瘤的数量还是疾病传播的速度。

No agreed-upon number of metastases delineates oligometastatic cancer from more widespread disease. Many studies have drawn the line at five, but that number was 'arbitrarily decided upon.' Part of the confusion is that oligometastatic cancer has no precise definition.

没有商定的转移数量将寡转移性癌症与更广泛的疾病区分开来。许多研究都将这一数字定为5，但这个数字是“任意决定的”部分困惑是寡转移癌没有确切的定义。

The term oligometastatic disease (OMD) was introduced into the clinical practice almost 30 years ago to delineate a patient group with few distant metastases that could benefit from a curative therapeutic strategy employing a local approach.

近30年前，寡转移性疾病（OMD）一词被引入临床实践，以描述一个远处转移很少的患者群体，这些患者群体可以从采用局部方法的治疗策略中受益。

The concept challenges the traditional view of cancer as a uniformly progressive and systemic disease, suggesting that some patients may benefit from aggressive local treatment to control or eradicate metastatic lesions.

这一概念挑战了癌症作为一种统一进行性和全身性疾病的传统观点，表明一些患者可能会从积极的局部治疗中受益，以控制或根除转移性病变。

The accurate diagnosis of the oligometastatic disease relies on advanced imaging techniques, such as positron emission tomography-computed tomography (PET-CT) and magnetic resonance imaging (MRI), to identify and localize metastatic lesions.

寡转移性疾病的准确诊断依赖于先进的成像技术，如正电子发射断层扫描计算机断层扫描（PET-CT）和磁共振成像（MRI），以识别和定位转移性病变。

In 2022, there were ~325,000 oligometastatic disease cases in the 7MM.

2022年，7MM中约有325000例寡转移性疾病病例。

In 2022, the highest number of oligometastatic were observed in non-small cell lung cancer, with ~27,000 cases, followed by colorectal cancer, with ~22,000 cases, in Japan.

2022年，日本非小细胞肺癌的寡转移率最高，约为27000例，其次是结直肠癌，约为22000例。

The United States accounted ~27,000 cases, ~86,000 cases, ~3,000 cases for synchronous, metachronous, and unknown types in 2022.

2022年，美国共有约27000例，约86000例，约3000例为同步，异时和未知类型。

EU4 and the UK accounted for ~40,000 oligorecurrent cases. Among EU4 and the UK, Germany accounted for the highest number of oligorecurrent cases.

EU4和英国约有40000例寡复发病例。在EU4和英国中，德国的寡发病例数量最多。

In 2022, Spain accounted for the lowest number of oligoreccurent cases out of all the 7MM countries accounting for around 6% of the total cases in the 7MM.

2022年，西班牙是所有700万国家中寡头复发病例数量最少的国家，约占700万国家总病例的6%。

Oligometastatic Disease Report Insights

寡转移性疾病报告见解

Oligometastatic Disease Patient Population

寡转移性疾病患者人群

Oligometastasis in Major Types of Cancers

主要类型癌症的寡转移

Type-specific Oligometastatic Cases

类型特异性寡转移病例

Oligorecurrence Cases

少复发病例

Oligorecurrence in Major Types of Cancers

主要类型癌症的少复发

Country-wise Epidemiology Distribution

国家流行病学分布

Oligometastatic Disease Report Key Strengths

寡转移性疾病报告的关键优势

Ten years Forecast

十年预测

The 7MM Coverage

7MM的覆盖范围

Oligometastatic Disease Epidemiology Segmentation

寡转移性疾病流行病学细分

Oligometastatic Disease Report Assessment

寡转移性疾病报告评估

Epidemiology Segmentation

流行病学细分

Current Diagnostic Practices

当前诊断实践

Key Topics Covered: 1. Key Insights2. Report Introduction3. Oligometastatic Disease Market Overview at a Glance3.1. Patient Share (%) Distribution of Oligometastatic Disease in 20193.2. Patient Share (%) Distribution of Oligometastatic Disease in 20324. Executive Summary of Oligometastatic Disease5.

涵盖的关键主题：1。关键见解2。报告简介3。寡转移性疾病市场概述3.1。20193年寡转移性疾病的患者比例（%）分布。20324年寡转移性疾病的患者比例（%）分布。寡转移性疾病的执行摘要5。

Disease Background and Overview5.1. Introduction5.2. Biological Basis for Oligometastatic Disease5.3. Terminologies Related to Oligometastatic Disease5.4. Major Types of Oligometastatic Cancers5.5. Diagnosis5.6. The European Organization for Research and Treatment of Cancer (EORTC): Consensus Recommendations on Characterization and Classification of Oligometastatic Disease6.

疾病背景和概述5.1。简介5.2。寡转移性疾病的生物学基础5.3。与寡转移性疾病相关的术语5.4。主要类型的寡转移癌5.5。诊断5.6。欧洲癌症研究与治疗组织（EORTC）：关于寡转移性疾病表征和分类的共识建议6。

Methodology7. Epidemiology and Patient Population7.1. Key Findings7.2. Assumptions and Rationale7.3. Total Oligometastatic Disease Cases in the 7MM7.4. The United States7.4.1. Total Oligometastatic Disease Cases in the United States7.4.2. Oligometastatic Disease Cases by Major Cancer Indications in the United States7.4.3.

方法学7。流行病学和患者人群7.1。关键发现7.2。假设和理性7.3。7MM7.4中的总寡转移性疾病病例。美国7.4.1。美国总寡转移性疾病病例7.4.2。美国主要癌症适应症的寡转移性疾病病例7.4.3。

Type-specific Cases of Oligometastatic Disease in the United States7.4.4. Total Oligorecurrent Cases in the United States7.4.5. Oligorecurrent Cases by Major Cancer Indications in the United States7.5. EU4 and the UK7.5.1. Total Oligometastatic Disease Cases in EU4 and the UK7.5.2. Oligometastatic Disease Cases by Major Cancer Indications in EU4 and the UK7.5.3.

美国寡转移性疾病的类型特异性病例7.4.4。美国总寡发病例7.4.5。美国主要癌症适应症的寡聚复发病例7.5。EU4和UK7.5.1。EU4和UK7.5.2中的总寡转移性疾病病例。EU4和UK7.5.3中主要癌症适应症的寡转移性疾病病例。

Type-specific Cases of Oligometastatic Disease in EU4 and the UK7.5.4. Total Oligorecurrent Cases in EU4 and the UK7.5.5. Oligorecurrent Cases by Major Cancer Indications in EU4 and the UK7.6. Japan7.6.1. Total Oligometastatic Disease Cases in Japan7.6.2. Oligometastatic Disease Cases by Major Cancer Indications in Japan7.6.3.

EU4和UK7.5.4中寡转移性疾病的类型特异性病例。EU4和UK7.5.5中的总寡复发病例。EU4和UK7.6中主要癌症适应症的寡复发病例。日本7.6.1。日本总寡转移性疾病病例7.6.2。日本主要癌症适应症的寡转移性疾病病例7.6.3。

Type-specific Cases of Oligometastatic Disease in Japan7.6.4. Total Oligorecurrent Cases in Japan7.6.5..

日本寡转移性疾病的类型特异性病例7.6.4。日本总寡复发病例7.6.5。。

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

关于ResearchAndMarkets.com ResearchAndMarkets.com是全球领先的国际市场研究报告和市场数据来源。我们为您提供有关国际和地区市场、关键行业、顶尖公司、新产品和最新趋势的最新数据。

Media Contact:

媒体联系人：

Research and MarketsLaura Wood, Senior Manager[email protected] For E.S.T Office Hours Call +1-917-300-0470For U.S./CAN Toll Free Call +1-800-526-8630For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716

研究与市场高级经理斯拉乌拉·伍德（SlauraWood），E.S.T办公时间电话+1-917-300-0470（美国）/CAN免费电话+1-800-526-8630（GMT办公时间电话+353-1-416-8900 U。S、 传真：646-607-1907传真（美国境外）：+353-1-481-1716

Logo - https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

徽标-https://mma.prnewswire.com/media/539438/research_and_markets_logo.jpg

SOURCE Research and Markets

来源研究和市场